B
Barni S
Researcher at Silesian University
Publications - 33
Citations - 384
Barni S is an academic researcher from Silesian University. The author has contributed to research in topics: Cancer & Interleukin 2. The author has an hindex of 9, co-authored 33 publications receiving 373 citations.
Papers
More filters
Journal ArticleDOI
The biological significance of soluble interleukin-2 receptors in solid tumors.
P. Lissoni,Barni S,Franco Rovelli,Simonetta Viviani,Georges J.M. Maestroni,A. Conti,G. Tancini +6 more
TL;DR: Serum mean levels of sIL-2R, measured with an enzyme immunoassay, were significantly higher in cancer patients than in controls; this difference was significant in all tumor histotypes, except small cell lung carcinoma.
Journal ArticleDOI
Endocrine and immune effects of melatonin therapy in metastatic cancer patients
TL;DR: It is suggested that melatonin may be of value in untreatable metastatic cancer patients, particularly in improving their PS and quality of life; moreover, based on its effects on the immune system, melatonin could be tested in association with other antitumor treatments.
Journal ArticleDOI
Increase in Soluble Interleukin-2 Receptor and Neopterin Serum Levels during Immunotherapy of Cancer with Interleukin-2
TL;DR: A positive correlation between SIL-2R and neopterin rise is shown, which would suggest a macrophage involvement in the stimulation of SIL- 2R release during IL-2 immunotherapy of cancer.
Journal ArticleDOI
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome.
Paolo Lissoni,Barni S,G. Cattaneo,Archili C,Sergio Crispino,Tancini G,D'Angelo L,Magni S,Fiorelli G +8 more
TL;DR: Results show that IL-2 administration may directly activate the complement system through the classical pathway, which might play a role in determining the increased vascular permeability.
Journal ArticleDOI
A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.
P Lissoni,A Ardizzoia,Barni S,F Paolorossi,G Tancini,S Meregalli,D Esposti,B. Zubelewicz,R Braczowski +8 more
TL;DR: This preliminary study suggests that the association of the pineal hormone MLT may make TMX effective also in ER-negative metastatic breast cancer patients.